Drugs / SRD441
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00882245 | Apr → Aug 2009 | atopic eczema | Serentis Ltd. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRD441 | “The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle-controlled study.” PMID 21039597 ↗ Sep 2010 |
| Action | Inhibit | “selectively inhibits Staphylococcal-derived aureolysin and matrix metalloproteinases (MMPs)” PMID 21039597 ↗ Sep 2010 |
| Modality | Other / unclassified | “SRD44 is a topically formulated novel protease inhibitor” PMID 21039597 ↗ Sep 2010 |